217 related articles for article (PubMed ID: 19480559)
1. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling.
Gibson CR; Bergman A; Lu P; Kesisoglou F; Denney WS; Mulrooney E
Xenobiotica; 2009 Sep; 39(9):637-48. PubMed ID: 19480559
[TBL] [Abstract][Full Text] [Related]
2. Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.
Fagerholm U
J Pharm Pharmacol; 2007 Oct; 59(10):1427-31. PubMed ID: 17910819
[TBL] [Abstract][Full Text] [Related]
3. Integrated in vitro analysis for the in vivo prediction of cytochrome P450-mediated drug-drug interactions.
McGinnity DF; Waters NJ; Tucker J; Riley RJ
Drug Metab Dispos; 2008 Jun; 36(6):1126-34. PubMed ID: 18356267
[TBL] [Abstract][Full Text] [Related]
4. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events.
Shaffer CL; Scialis RJ; Rong H; Obach RS
Biopharm Drug Dispos; 2012 Mar; 33(2):72-84. PubMed ID: 22213407
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist.
Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM
Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556
[TBL] [Abstract][Full Text] [Related]
6. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
Grime KH; Bird J; Ferguson D; Riley RJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
[TBL] [Abstract][Full Text] [Related]
8. Prediction of human pharmacokinetics - renal metabolic and excretion clearance.
Fagerholm U
J Pharm Pharmacol; 2007 Nov; 59(11):1463-71. PubMed ID: 17976256
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
[TBL] [Abstract][Full Text] [Related]
10. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
De Buck SS; Mackie CE
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different approaches to predict metabolic drug-drug interactions.
Einolf HJ
Xenobiotica; 2007; 37(10-11):1257-94. PubMed ID: 17968745
[TBL] [Abstract][Full Text] [Related]
14. Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):803-28. PubMed ID: 17637173
[TBL] [Abstract][Full Text] [Related]
15. Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds.
Fura A; Vyas V; Humphreys W; Chimalokonda A; Rodrigues D
Biopharm Drug Dispos; 2008 Nov; 29(8):455-68. PubMed ID: 18989850
[TBL] [Abstract][Full Text] [Related]
16. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.
De Buck SS; Sinha VK; Fenu LA; Nijsen MJ; Mackie CE; Gilissen RA
Drug Metab Dispos; 2007 Oct; 35(10):1766-80. PubMed ID: 17620347
[TBL] [Abstract][Full Text] [Related]
17. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.
Obach RS; Baxter JG; Liston TE; Silber BM; Jones BC; MacIntyre F; Rance DJ; Wastall P
J Pharmacol Exp Ther; 1997 Oct; 283(1):46-58. PubMed ID: 9336307
[TBL] [Abstract][Full Text] [Related]
18. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
19. Computational prediction of oral drug absorption based on absorption rate constants in humans.
Linnankoski J; Mäkelä JM; Ranta VP; Urtti A; Yliperttula M
J Med Chem; 2006 Jun; 49(12):3674-81. PubMed ID: 16759110
[TBL] [Abstract][Full Text] [Related]
20. Quantitative prediction of human clearance guiding the development of Raltegravir (MK-0518, isentress) and related HIV integrase inhibitors.
Laufer R; Paz OG; Di Marco A; Bonelli F; Monteagudo E; Summa V; Rowley M
Drug Metab Dispos; 2009 Apr; 37(4):873-83. PubMed ID: 19144773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
